Search hospitals
>
Minnesota
>
Saint Paul
Minnesota Oncology Hematology PA-Maplewood
Claim this profile
Saint Paul, Minnesota 55109
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Breast cancer
Conducts research for Pancreatic Cancer
475 reported clinical trials
14 medical researchers
Summary
Minnesota Oncology Hematology PA-Maplewood is a medical facility located in Saint Paul, Minnesota. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Pancreatic Cancer and other specialties. Minnesota Oncology Hematology PA-Maplewood is involved with conducting 475 clinical trials across 505 conditions. There are 14 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.
Area of expertise
Breast Cancer
Minnesota Oncology Hematology PA-Maplewood has run 87 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Minnesota Oncology Hematology PA-Maplewood has run 68 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
David M. King
Park Nicollet Clinic - Saint Louis Park
9 years of reported clinical research
Daniel M. Anderson
Abbott-Northwestern Hospital
7 years of reported clinical research
Yan Ji
Regions Hospital
2 years of reported clinical research
Pamala A. Pawloski
Park Nicollet Clinic - Saint Louis Park
6 years of reported clinical research
Clinical Trials running at Minnesota Oncology Hematology PA-Maplewood
Lung Cancer
Prostate Cancer
Bladder Cancer
Breast Cancer
Colorectal Cancer
Esophageal cancer
Kidney Cancer
Ovarian Cancer
Breast cancer
Cancer
Stereotactic Radiosurgery vs Whole-Brain Radiotherapy
for Brain Metastasis from Lung Cancer
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Whole brain radiation therapy delivers a low dose of radiation to the entire brain including the normal brain tissue. Hippocampal avoidance during whole-brain radiation therapy (HA-WBRT) decreases the amount of radiation that is delivered to the hippocampus which is a brain structure that is important for memory. The drug, memantine, is also often given with whole brain radiotherapy because it may decrease the risk of side effects related to thinking and memory. Stereotactic radiosurgery may decrease side effects related to memory and thinking compared to standard of care HA-WBRT plus memantine.
Recruiting
2 awards
Phase 3
15 criteria
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting
2 awards
Phase 3
4 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Minnesota Oncology Hematology PA-Maplewood?
Minnesota Oncology Hematology PA-Maplewood is a medical facility located in Saint Paul, Minnesota. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Pancreatic Cancer and other specialties. Minnesota Oncology Hematology PA-Maplewood is involved with conducting 475 clinical trials across 505 conditions. There are 14 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.
Where is Minnesota Oncology Hematology PA-Maplewood located?
**Minnesota Oncology Hematology PA-Maplewood** - **Address:** 310 Smith Ave N, Suite 100, Saint Paul, MN 55102 - **Directions:** Take I-94 E to exit 238B for US-10 E towards Maplewood. Continue on US-10 E to Smith Ave N.
Who should I call to ask about financial aid or insurance network?
**Minnesota Oncology Hematology PA-Maplewood Financial and Insurance Assistance:** - **Financial Assistance:** Contact the Patient Benefit Representative at your clinic or call (844) 317-4673 for help with insurance claims and finding financial assistance through nationally recognized programs. - **Insurance Inquiries:** Call (844) 317-4673 for assistance with insurance-related questions. Minnesota Oncology submits claims to most major insurance carriers on your behalf. - **Pharmacy Inquiries:** For assistance with medications, pain management, and drug interactions, contact the Maplewood Cancer Center pharmacist at (651) 255-8480. They also help with insurance approval and obtaining financial assistance.
What insurance does Minnesota Oncology Hematology PA-Maplewood accept?
Minnesota Oncology Hematology PA-Maplewood accepts a wide range of insurance plans, including Aetna, Medicare, PPO, CMS, BCBS Blue Card, Cigna, Anthem, First Health, Wellmark, UHC Community & State - Direct, and Medica. They participate in value-based payment models with Blue Cross Blue Shield of Minnesota to deliver best-in-class results at a lower overall cost.
What awards or recognition has Minnesota Oncology Hematology PA-Maplewood received?
Minnesota Oncology Hematology PA-Maplewood, located in Saint Paul, Minnesota, is the Twin Cities' largest and most experienced cancer treatment provider. It has been designated as a Blue Distinction® Center for Cancer Care by Blue Cross Blue Shield Minnesota, highlighting its commitment to delivering high-quality, cost-effective cancer care.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.